← All trials
NCT03572491
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 18, 2017
- Primary completion
- May 21, 2018
- Completion date
- May 21, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 2000
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Research Institute for Biological Safety ProblemsLead sponsor
- Asfendiyarov Kazakh National Medical UniversityCollaborator
- Research Institute of Influenza, RussiaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.